Molecular TherapyImmunologyPeer-reviewed journal article
Synchronized Latency Reversal and Immune Clearance by a Multifunctional Fusion Protein Enables HIV-1 Reservoir Reduction
Fei Luo, Yinghui Cao, N K Liu, Xiaowei Wang, Wenjia Hu, Yajun Yan, Xiaoqing Xie, Dongmei JiangiD, Yangyang Xu, Jun WangiD, Hongyu Wang, Zhenyang YuiD, Peng Qian, Shicheng WaniD, Zhida LiuiD, Gong Yan, Tielong CheniD, Shihui SongiD, Yong XiongiD, Xiaoping TangiD, Linghua LiiD, Li WangiD, Haisheng YuiD, Liang ChengiD
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- top 47%
Abstract
Strategies that concurrently reactivate latent reservoirs and enhance immune-mediated clearance hold significant promise for achieving an HIV cure. Here, we developed hyperIL-15xsCD4-Fc (15xsCD4-Fc), a fusion protein that integrates latency reactivation, targeted immune engagement, and effector-mediated killing into a single molecule. This agent not only potently reverses HIV-1 latency in CD4+ T cells from people living with HIV-1 (PLWH) through coordinated IL-15 receptor signaling and sCD4-mediated HIV-1 envelope (Env) engagement, but also enhances antigen-specific CD8+ T cell response in PBMCs derived from PLWH. Furthermore, 15xsCD4-Fc enables Env-specific elimination of reactivated latently infected cells by NK cells while preventing off-target cytotoxicity. In PBMCs from PLWH, 15xsCD4-Fc reduced replication-competent HIV-1 DNA by 93.8%. In antiretroviral treated HIV-1-infected humanized mice, the molecule demonstrated both safety and efficacy in diminishing viral reservoir in lymphoid organs. This spatiotemporally coupled approach to reservoir exposure and immune recognition establishes a clinically viable strategy for clearing the HIV-1 reservoir. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=195 SRC="FIGDIR/small/693434v1_ufig1.gif" ALT="Figure 1"> View larger version (44K): org.highwire.dtl.DTLVardef@8f8f0org.highwire.dtl.DTLVardef@10f63f7org.highwire.dtl.DTLVardef@16c1de2org.highwire.dtl.DTLVardef@11e1787_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: proteomics
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- approach: experimental assay
- approach: wet-lab / biochemical assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Bispecific Biologic That Robustly Reverses HIV-1 and SIV Latency
Yaoxing Huang, Manoj S. Nair, … David D Ho·bioRxiv·Oct 8, 2026
- Leveraging HIV-Specific CAR T Cells and Rapamycin Treatment in Kick-and-Kill HIV Cure Approaches
Nishad S. Maggirwar, Jose A. Moran, … Matthew D. Marsden·bioRxiv·Jan 15, 2026
- Synergistic latency reversal by the IAP antagonist AZD5582 and BET inhibitor JQ1, combined with Nef ablation, facilitates immune-mediated elimination of latently HIV-1-infected T-cells
Dylan Postmus, Sui Ting Hui, … Christine Goffinet·bioRxiv·Aug 6, 2025
- CD24-Fc resolves inflammation and rescues CD8 T cells with polyfunctionality during HIV-1 infection under cART
Guangming Li, Jianping Ma, … Lishan Su·PLoS PathogensPeer-reviewed·Aug 8, 2025
- Targeted Bacteriophage T4 Nanoparticles Reverse HIV-1 Latency in CD4+ Human T Cells
- Broadly neutralizing antibody-secreting CAR-T cells elicit Fc-mediated effector functions in vitro and suppress HIV in humanized mice
Zoe Stylianidou, Sarah Gerlo, … Wojciech Witkowski·Frontiers in ImmunologyPeer-reviewed·May 8, 2026